New combo therapy shows promise for early psoriatic arthritis patients
NCT ID NCT04108468
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding GOLimumab to methotrexate works better than methotrexate alone for people with very early psoriatic arthritis (PsA). 84 adults with active PsA diagnosed within the last 2 years took part. The main goal was to see if the combination improved disease activity scores at 24 weeks. Results help doctors choose the best treatment to control PsA early on.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Leeds Teaching Hospitals NHS Trust
Leeds, West Yorkshire, LS7 4SA, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm psoriatic arthritis?
- Can a once-daily pill tame psoriatic arthritis in everyday life?
- A single blood test may reveal whether a gene tied to transplant outcomes influences psoriatic arthritis risk.
- Can a 4-Minute chat rival a Dietitian's hour for heart health?
- Your plate may fight psoriatic arthritis: diet study tests food as medicine
- Real-World study tests whether aggressive early treatment improves psoriatic arthritis outcomes